Registry-only phase 2 and 3 trials that name triple-negative breast cancer in their title or conditions, recorded from ClinicalTrials.gov during the triple-negative breast cancer deep dive. 213 records carry it: 213 trials.
A phase 3 trial of epirubicin, cyclophosphamide and paclitaxel / nab-paclitaxel in triple-negative breast cancer, run by Fudan University, now recruiting.
A phase 2 trial of cisplatin and carboplatin in triple-negative breast cancer, run by ImmuneOnco Biopharmaceuticals (Shanghai) Inc., not yet recruiting.
A phase 2 trial of tislelizumab and capecitabine in triple-negative breast cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, now recruiting.
A phase 3 trial of paclitaxel / nab-paclitaxel and carboplatin in triple-negative breast cancer, run by Tata Memorial Hospital, active but no longer recruiting.
A phase 3 trial of izalontamab brengitecan and nab-paclitaxel in triple-negative breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., not yet recruiting.
A phase 2 trial of sacituzumab govitecan, toripalimab and nab-paclitaxel in triple-negative breast cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, not yet recruiting.
A phase 1/2 trial of datopotamab deruxtecan and durvalumab in triple-negative breast cancer, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting.
A phase 2 trial of camrelizumab and nab-paclitaxel in triple-negative breast cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, not yet recruiting.
A phase 2 trial of epirubicin, pirarubicin and cyclophosphamide in triple-negative breast cancer, run by Chinese Academy of Medical Sciences, now recruiting.
A phase 3 trial of epirubicin, cyclophosphamide and carboplatin in triple-negative breast cancer, run by Shanghai Jiao Tong University School of Medicine, active but no longer recruiting.
A phase 2 trial of nab-paclitaxel, rivoceranib (apatinib) and bevacizumab in triple-negative breast cancer, run by The First Affiliated Hospital of Bengbu Medical University, now recruiting.
A phase 1/2 trial of cyclophosphamide and aldesleukin (high-dose il-2) in triple-negative breast cancer, run by Hadassah Medical Organization, now recruiting.
A phase 2 trial of atezolizumab, cyclophosphamide and vinorelbine in triple-negative breast cancer, run by European Institute of Oncology, now recruiting.
A phase 2 trial of paclitaxel / nab-paclitaxel, carboplatin and pembrolizumab in triple-negative breast cancer, run by M.D. Anderson Cancer Center, not yet recruiting.
A phase 2 trial of cadonilimab in triple-negative breast cancer, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, now recruiting.
A phase 2 trial of camrelizumab, doxorubicin, cyclophosphamide, carboplatin and other drugs in triple-negative breast cancer, run by Blokhin's Russian Cancer Research Center, not yet recruiting.
A phase 3 trial of epirubicin, paclitaxel / nab-paclitaxel and carboplatin in triple-negative breast cancer, run by Fudan University, active but no longer recruiting.
A phase 2 trial of anlotinib, benmelstobart and capecitabine in triple-negative breast cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, now recruiting.
A phase 2 trial of iparomlimab and tuvonralimab and olaparib in triple-negative breast cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.
A phase 2 trial of palbociclib, paclitaxel / nab-paclitaxel and carboplatin in triple-negative breast cancer, run by Medical University of Gdansk, not yet recruiting.